Fundsmith 13F: Cuts Stryker (SYK) Stake by $207M

Fundsmith Trims Stryker Stake

Fundsmith pared back its investment in Stryker Corporation (NYSE:SYK) according to a Form 13F filed with the U.S. Securities and Exchange Commission on May 15, 2026. The fund cut its position by a 16.9% margin, selling 626,095 shares during the reporting period. That left Fundsmith with 3.06 million shares in the medical device maker.

Stryker Stock Performance and Trading Range

Stryker shares recently traded at $330.52, sitting between its 52-week low of $267.00 and its high of $392.55. The company trades close to its 200-day moving average of $326.94. Note that 13F filings are backward-looking and capture holdings from past quarters, meaning this report may not reflect the fund's current position today.

Recent Earnings and Financial Health

Stryker generated $25.83 billion in trailing revenue with a 9.4% growth rate, backed by an EPS of $9.65. The company posted a net margin of 14.4% alongside a 16.5% return on equity. Investors can expect the next earnings report on October 29, 2026.

Stryker Dividend Payments

Stryker pays an annual dividend yielding 1.2%, backed by a payout ratio of 36.1%.

Wall Street Analyst Views

Wall Street firms continue to adjust their outlooks on the medical device maker. On October 12, 2026, BTIG maintained a buy rating while lowering its price target to $316.00. Truist Securities kept a hold rating with a $310.00 target on October 7, 2026, while Barclays initiated coverage with an overweight rating and a $375.00 target on the same day. Stifel maintained a buy rating on September 30, 2026, lowering its target to $330.00, and TD Cowen maintained a hold rating with a reduced target of $298.00 on September 22, 2026. Canaccord Genuity kept a buy rating on September 18, 2026, adjusting its target to $385.00. Citigroup maintained a buy rating with a $360.00 target on September 10, 2026, and Wells Fargo kept an overweight rating with a $348.00 target on September 9, 2026.

Inside Stryker Corporation

Stryker Corporation operates as a medical technology business through two main segments focused on MedSurg and Orthopaedics. The company builds surgical equipment, smart robotics suites like Mako, and total joint replacement implants for hospitals and healthcare providers worldwide.

What to Watch at Stryker Corporation

Investors tracking Fundsmith will look to upcoming regulatory filings for further adjustments to its healthcare holdings. Stryker's next quarterly update in late October will provide fresh figures on segment growth and profit margins.